Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

October 13, 2014

Study Completion Date

November 27, 2017

Conditions
Multiple Myeloma
Interventions
DRUG

Ixazomib

Ixazomib capsules

DRUG

Lenalidomide

Lenalidomide capsules

DRUG

Dexamethasone

Dexamethasone Tablets

Trial Locations (20)

10021

Memorial Sloan Kettering Cancer Center, New York

20850

Associates of Oncology/Hematology PC, Rockville

22031

Virginia Cancer Care Specialist, Fairfax

Virginia Cancer Specialists PC, Fairfax

27705

Duke University Medical Center, Durham

31406

Mount Sinai Hospital, New York

33612

H Lee Moffitt Cancer Center and Research Institute, Tampa

37203

SCRI Tennessee Oncology Nashville, Nashville

43210

Ohio State University, Columbus

43623

Mercy St Anne Hospital, Toledo

48109

University of Michigan, Ann Arbor

48910

Michigan State University, Lansing

60637

University of Chicago Medical Center, Chicago

75246

Baylor Sammons Cancer Center, Dallas

91010

City of Hope National Medical Center, Duarte

94305

Stanford University, Stanford

94704

UCSF Medical Center, Berkeley

97239

Oregon Health and Science University, Portland

02115

Dana Farber Cancer Institute, Boston

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT01383928 - Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma | Biotech Hunter | Biotech Hunter